The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 14, 2020
Filed:
Aug. 08, 2016
Centre Hospitalier National D'ophtalmologie Quinze-vingts, Paris, FR;
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Imagine Institut Des Maladies Genetiques Necker Enfants Malades, Paris, FR;
Assistance Publique—hopitaux DE Paris, Paris, FR;
Universite Paris Descartes, Paris, FR;
Yves Colin, Vanves, FR;
Jean-Francois Girmens, Paris, FR;
Olivier Hermine, Paris, FR;
Emmanuel Heron, Chatenay-malabry, FR;
Michel Paques, Paris, FR;
CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS, Paris, FR;
INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICAL (INSERM), Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES, Paris, FR;
ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris, FR;
UNIVERSITE PARIS DESCARTES, Paris, FR;
Abstract
The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.